Congratulations Merck! Your tactics and policies have managed to alienate all of the Cubicin, Sivextro, and Zerbaxa customers in record time. Reducing the Cubicin discounts for top home infusion and physician owned infusion clinics was a stroke of genius. Disallowing field intervention to assist offices with the Sivextro patient access program and then further complicating the application process was outstanding. And best of all, changing a policy in the middle of a drug launch that negatively affects hospitals and their ability to test for Zerbaxa susceptibilities is sheer brilliance! The exquisite timing of all of these changes to occur when the field was receiving little to no sales data for Cubicin and Sivextro made the declines very stealthy indeed. The impact you have made with now former Cubicin, Sivextro, and Zerbaxa customers is remarkable and appreciated by your competiton
To make the sabotage on the sales complete all you need to do now is to add in some hefty price increases, a bit more field disruption, and for good measure let’s throw in some manufacturing and supply issues in the future. The sales job is much too easy for us here in the field so please continue to keep us challenged and on our toes.
Merck, how is that $9 billion purchase of Cubist working out for you? For your next acquisition you should consider buying Apple, with your expertise you could easily turn it into the next Blackberry!
To make the sabotage on the sales complete all you need to do now is to add in some hefty price increases, a bit more field disruption, and for good measure let’s throw in some manufacturing and supply issues in the future. The sales job is much too easy for us here in the field so please continue to keep us challenged and on our toes.
Merck, how is that $9 billion purchase of Cubist working out for you? For your next acquisition you should consider buying Apple, with your expertise you could easily turn it into the next Blackberry!